From WikiProjectMed
Jump to navigation Jump to search
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetIL-6 receptor
Trade namesActemra, RoActemra
Clinical data
  • AU: C
  • US: C (Risk not ruled out)
Routes of
Intravenous infusion, subcutaneous injection
External links
License data
Legal status
  • AU: S4 (Prescription only)
  • US: ℞-only
  • In general: ℞ (Prescription only)
Elimination half-life8–14 days during steady state (dependent on concentration)
Chemical and physical data
Molar mass144987.06 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Tocilizumab, also known as atlizumab and sold under the trade name Actemra, is an immunosuppressive drug, mainly for the treatment of rheumatoid arthritis (RA) and systemic juvenile idiopathic arthritis.

It is a humanized monoclonal antibody against the interleukin-6 receptor (IL-6R). Interleukin 6 (IL-6) is a cytokine that plays an important role in immune response and is implicated in the pathogenesis of many diseases, such as autoimmune diseases, multiple myeloma and prostate cancer. It was developed by Hoffmann–La Roche and Chugai.[1]

Medical uses

The drug is administered by monthly intravenous infusions. An infusion takes about an hour.[2] An alternative formulation for subcutaneous injection was approved in October 2013.[3]

Rheumatoid arthritis

Tocilizumab is used for the treatment of moderate to severe rheumatoid arthritis, applied in combination with methotrexate, if other drugs like disease-modifying antirheumatic drugs (DMARDs) and TNF alpha blockers have proven to be ineffective or were not tolerated. It can be used as a monotherapy for patients who do not tolerate methotrexate.[4][5] The drug slows down the progression of the disease and can improve physical function of patients.[6]

Systemic juvenile idiopathic arthritis

The treatment of systemic juvenile idiopathic arthritis is similar to RA treatment: tocilizumab is combined with methotrexate unless the latter is not tolerated. General safety and effectiveness is established for children of two years and older.[7]

In 2011 the US FDA approved tocilizumab for the treatment of the orphan disease, active systemic juvenile idiopathic arthritis (SJIA), a rare and severe form of arthritis affecting children.[8]

Castleman's disease

In Japan, tocilizumab is also approved for the treatment of Castleman's disease,[4][9] a rare benign tumor of B cells.

Neuromyelitis optica

Early case reports suggest tocilizumab might be effective in otherwise refractory neuromyelitis optica (NMO, Devic's disease).[10][11][12][13]

Giant cell arteritis

In May 2017, tocilizumab was FDA approved for giant cell (temporal) arteritis.[14]

Cytokine release syndrome

On 30 August 2017, the FDA approved tocilizumab for cytokine release syndrome, a side effect of CAR-T cell therapies.[15]

Pregnancy and lactation

No clinical studies evaluating the risk for fetuses are available. A study using large doses of tocilizumab in pregnant animals has found an increased likelihood for spontaneous abortion. It is not known whether the drug is secreted into the breast milk, nor if this would pose a risk for the nursling.[5]


The application of tocilizumab is contraindicated during acute infections, as well as under latent tuberculosis.[16]

Adverse effects

The most common adverse effects observed in clinical trials were upper respiratory tract infections (more than 10% of patients), nasopharyngitis (common cold), headache, and high blood pressure (at least 5%). The enzyme alanine transaminase was also elevated in at least 5% of patients, but in most cases without symptoms. Elevated total cholesterol levels were common.[17] Among the less common side effects were dizziness, various infections, as well as reactions of the skin and mucosae like mild rashes, gastritis and mouth ulcer. Rare but severe reactions were gastrointestinal perforations (0.26% in six months) and anaphylaxis (0.2%).[16]


There are no certain interactions with other drugs. The blood plasma levels of simvastatin were reduced by 57% after a single dose of tocilizumab, but it is not known whether this is clinically relevant. A possible mechanism is that the elevated IL-6 levels of patients with RA suppress the biosynthesis of various cytochrome P450 enzymes, notably CYP1A2, CYP2C9, CYP2C19 and CYP3A4. Tocilizumab lowers IL-6 and thus normalises cytochrome levels, increasing the metabolization of simvastatin (and possibly other cytochrome metabolised drugs).[16]

Mechanism of action

Besides other functions, interleukin 6 (IL-6) is involved in the development of immunological and inflammatory reactions. Some autoimmune diseases like RA are associated with abnormally high IL-6 levels. Tocilizumab binds soluble as well as membrane bound interleukin-6 receptors, hindering IL-6 from exerting its pro-inflammatory effects.[16][18] It has been noted that the membrane bound form and soluble form of the IL-6 receptor may have different effects in the pathogenesis of rheumatoid arthritis with the soluble form being more implicated in disease progression.[19]


Interleukin 6 and its receptor were discovered and cloned at Osaka University, Japan, by Tadamitsu Kishimoto in the 1980s. In 1997, Chugai Pharmaceuticals began the clinical development of tocilizumab for the treatment of rheumatoid arthritis. Clinical studies for Castleman's disease and systemic juvenile idiopathic arthritis started in 2001 and 2002, respectively. Hoffmann–La Roche co-developed the drug due to a license agreement in 2003.[20]

Data presented in 2008 showed the effectiveness of tocilizumab in combination therapy with methotrexate for RA treatment.[21] In further studies, it was effective and generally well tolerated when administered either as monotherapy or in combination with conventional DMARDs in adult patients with moderate to severe rheumatoid arthritis.[22]

In June 2005, tocilizumab was approved in Japan for Castleman's disease.[4] In January 2009, the drug was approved by the European Medicines Agency (EMA) as RoActemra for the treatment of rheumatoid arthritis under the mentioned restrictions. On 11 January 2010, it was approved by the U.S. Food and Drug Administration (US FDA) as Actemra for the same purpose.[23] Tocilizumab was approved by Australia's Therapeutic Goods Administration on 27 May 2009[24] and was listed on the Pharmaceutical Benefits Scheme from 1 August 2010.[25] In New Zealand, tocilizumab was approved for distribution in July 2009,[26] and Pharmac approved subsidising it with special authority restrictions on 1 July 2013 for systemic juvenile idiopathic arthritis[27] and 1 July 2014 for rheumatoid arthritis.[28] The FDA approved tocilizumab for the treatment of systemic juvenile idiopathic arthritis for children from two years of age in April 2011, and the EMA followed in August the same year.

Tocilizumab is marketed by Chugai in some countries, especially in Japan and other Asian countries, and jointly by Chugai and Roche (Hoffmann–La Roche's holding company) in others, for example Great Britain, France and Germany.[20]


The intensity of IL-6 in cancer cells from people with ovarian cancer is associated with poor prognosis, and in cell culture a different anti-IL-6 antibody (siltuximab) reduced IL-6 signaling and showed favorable effects in an animal model of the disease; however, the drug showed no clear effects when tested in a phase II clinical trial in people with advanced ovarian cancer.[29] The trial investigators later showed that in high-grade ovarian cancer cells, anti-IL6 antibodies reduced the activation of STAT3 (its major downstream transcription factor), leading to increased activity of the epidermal growth factor receptor (EGFR) pathway, which is thought to confer resistance to several cancer therapies.[30] The investigators then showed that inhibiting this pathway with the EGFR inhibitor gefitinib inhibited tumor growth was in cell culture and animals of the disease, offering a potential rationale for combining anti-IL6 antibodies with gefitinib to treat advanced-stage ovarian cancer.[30]

Tocilizumab is being studied for pulmonary arterial hypertension (PAH).[31] Tocilizumab is currently under evaluation in a multicenter clinical trial (ALL-IN) for the prevention of acute cellular rejection in status post heart transplant patients.[32]


China's National Health Commission included the use of tocilizumab in guidelines to treat coronavirus disease 2019 (COVID-19) patients.[33] In March 2020, China approved tocilizumab for the treatment of inflammation in patients with the coronavirus SARS-CoV-2. As of June 2020, there is no evidence whether this treatment is effective.[34] Chinese health officials say that only 21 patients have been asked to use this medicine.[35] The same month, a randomized study, at 11 locations in China was conducted to compare favipiravir versus tocilizumab versus both.[36]

On 11 March 2020, Italian physician Paolo Ascierto reported that tocilizumab appeared to be effective in three severe cases of COVID-19 in Italy.[37] On 14 March 2020, three of the six treated patients in Naples had shown signs of improvement prompting the Italian Pharmacological Agency (AIFA) to expand testing in five other hospitals.[38] Roche and the WHO have each launched separate trials for its use in severe COVID-19 cases.[39]

Tocilizumab was among the drugs noted as treatments for COVID-19 in a study of major hospitals in the U.S. that determined that abnormal liver tests were occurring in most hospitalized patients with COVID‐19 and may be associated with poorer clinical outcomes.[40] Several medications used in the treatments during the study were found to be associated with peak hospitalization liver transaminase elevations >5x ULN. Tocilizumab was significantly associated in the relationship between the drugs used to treat the disease and abnormal liver tests, which has prompted studies being conducted to determine whether the abnormal tests were due to the disease or to drug-induced liver injury, according to Michael Nathanson, director of the Yale Liver Center and co-author of the study.[41]

Roche announced on 29 July 2020 that its randomized double-blind trial of tocilizumab in the treatment of pneumonia in Covid patients had shown no benefits of the drug.[42]

On 21 October 2020, another research was published that concluded that "tocilizumab was not effective for preventing intubation or death in moderately ill hospitalized patients with Covid-19".[43]

See also


  1. Venkiteshwaran, Adith (2009). "Tocilizumab". mAbs. 1 (5): 432–438. doi:10.4161/mabs.1.5.9497. PMC 2759492. PMID 20065633. Archived from the original on 8 March 2012.
  2. Haberfeld, H, ed. (2009). Austria-Codex (in German) (2009/2010 ed.). Vienna: Österreichischer Apothekerverlag. ISBN 978-3-85200-196-8.CS1 maint: unrecognized language (link)
  3. "Genentech Gains FDA Approval for New Subcutaneous Formulation of Actemra for use in Adult Patients Living with Moderately to Severely Active Rheumatoid Arthritis". Genentech. 21 October 2013. Archived from the original on 8 September 2017.
  4. 4.0 4.1 4.2 "RoActemra approved in Europe to treat patients suffering from Rheumatoid Arthritis" (Press release). Hoffmann–La Roche. 2009-01-21. Archived from the original on 2009-02-28. Retrieved 2009-01-05. CS1 maint: discouraged parameter (link)
  5. 5.0 5.1 "Assessment report for RoActemra" (PDF). European Medicines Agency.
  6. Roy Fleischmann; et al. (2009). "LITHE: Tocilizumab Inhibits Radiographic Progression and Improves Physical Function in Rheumatoid Arthritis (RA) Patients (Pts) at 2 Yrs with Increasing Clinical Efficacy Over Time". ACR. Cite journal requires |journal= (help)
  7. Chaitow, J; De Benedetti, F; Brunner, H; et al. (2010). "Tocilizumab in Patients With Systemic Juvenile Idiopathic Arthritis: Efficacy Data From the Placebo-Controlled 12-Week Part of the Phase 3 TENDER Trial" (PDF). Arthritis & Rheumatism. 62 (Supplement 10): 1434.
  8. FDA Approves ACTEMRA® (tocilizumab) for the Treatment of Systemic Juvenile Idiopathic Arthritis (SJIA), South San Francisco, California: Genentech, April 15, 2011, archived from the original on 1 October 2018, retrieved July 20, 2015 CS1 maint: discouraged parameter (link)
  9. Matsuyama M, Suzuki T, Tsuboi H, et al. (2007). "Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease". Intern. Med. 46 (11): 771–4. doi:10.2169/internalmedicine.46.6262. PMID 17541233.
  10. Komai T, Shoda H, Yamaguchi K, Sakurai K, Shibuya M, Kubo K, Takahashi T, Fujio K, Yamamoto K (Dec 9, 2013). "Neuromyelitis optica spectrum disorder complicated with Sjogren syndrome successfully treated with tocilizumab: A case report". Mod Rheumatol. 26 (2): 294–6. doi:10.3109/14397595.2013.861333. PMID 24313919. S2CID 21195912.
  11. Kieseier BC, Stüve O, Dehmel T, Goebels N, Leussink VI, Mausberg AK, Ringelstein M, Turowski B, Aktas O, Antoch G, Hartung HP; Stüve; Dehmel; Goebels; Leussink; Mausberg; Ringelstein; Turowski; Aktas; Antoch; Hartung (Mar 1, 2013). "Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses". JAMA Neurol. 70 (3): 390–393. doi:10.1001/jamaneurol.2013.668. PMID 23599943.CS1 maint: multiple names: authors list (link)
  12. Ayzenberg I, Kleiter I, Schröder A, Hellwig K, Chan A, Yamamura T, Gold R; Kleiter; Schröder; Hellwig; Chan; Yamamura; Gold (Mar 1, 2013). "Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy". JAMA Neurol. 70 (3): 394–397. doi:10.1001/jamaneurol.2013.1246. PMID 23358868.CS1 maint: multiple names: authors list (link)
  13. Araki M, Aranami T, Matsuoka T, Nakamura M, Miyake S, Yamamura T; Aranami; Matsuoka; Nakamura; Miyake; Yamamura (Jul 2013). "Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab". Mod Rheumatol. 23 (4): 827–831. doi:10.1007/s10165-012-0715-9. PMC 3713263. PMID 22782533.CS1 maint: multiple names: authors list (link)
  14. "FDA Approves Actemra (tocilizumab) Subcutaneous Injection for Giant Cell Arteritis".
  15. "FDA approves tisagenlecleucel for B-cell ALL and tocilizumab for cytokine release syndrome". US FDA. 30 August 2017.
  16. 16.0 16.1 16.2 16.3 Dinnendahl, V; Fricke, U, eds. (2010). Arzneistoff-Profile (in German). 4 (23 ed.). Eschborn, Germany: Govi Pharmazeutischer Verlag. ISBN 978-3-7741-9846-3.CS1 maint: unrecognized language (link)
  17. Genovese, M. C.; McKay, J. D.; Nasonov, E. L.; Mysler, E. F.; Da Silva, N. A.; Alecock, E.; Woodworth, T.; Gomez-Reino, J. J. (2008). "Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study". Arthritis & Rheumatism. 58 (10): 2968–80. doi:10.1002/art.23940. PMID 18821691.
  18. Jones, G; Sebba, A; Gu, J; Lowenstein, MB; Calvo, A; Gomez-Reino, JJ; Siri, DA; Tomsic, M; et al. (2010). "Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study". Annals of the Rheumatic Diseases. 69 (1): 88–96. doi:10.1136/ard.2008.105197. PMC 3747519. PMID 19297346.
  19. Kallen, K.J. (2002). "The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases". Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1592 (3): 323–343. doi:10.1016/s0167-4889(02)00325-7. PMID 12421676.
  20. 20.0 20.1 Markus Harwart (2008). "Die Entwicklung von Tocilizumab" [The development of tocilizumab] (in German). Krankenpflege-Journal. Archived from the original on 15 October 2018.CS1 maint: unrecognized language (link)
  21. "Jab hope for rheumatoid arthritis". October 27, 2008 – via
  22. Oldfield, V; Dhillon, S; Plosker, GL (2009). "Tocilizumab". Drugs. 69 (5): 609–632. doi:10.2165/00003495-200969050-00007. PMID 19368420. Archived from the original on 2011-10-08. CS1 maint: discouraged parameter (link)
  23. "Roche: FDA Approves Actemra For Rheumatoid Arthritis". The Wall Street Journal. 11 January 2010. Archived from the original on January 14, 2010. CS1 maint: discouraged parameter (link)
  24. "Australian Drug Evaluation Committee 263rd meeting resolutions". Therapeutic Goods Administration. 27 May 2009. Archived from the original on 20 August 2009.
  25. "Anakinra (Kineret) to be deleted from the PBS". National Prescribing Service Limited. 1 August 2010. Archived from the original on 3 June 2012. CS1 maint: discouraged parameter (link)
  26. Richards, Mark (20 July 2009). "Consent to the Distribution of New Medicines". New Zealand Gazette. 2009 (105): 2418. Retrieved 9 June 2015. CS1 maint: discouraged parameter (link)
  27. "Approval of proposal involving pegfilgrastim and tocilizumab" (PDF). Pharmaceutical Management Agency. 24 May 2013. Retrieved 9 June 2015. CS1 maint: discouraged parameter (link)
  28. "Decision to widen access to tocilizumab (Actemra) for rheumatoid arthritis in patients who are unable to be treated with methotrexate" (PDF). Pharmaceutical Management Agency. 14 May 2014. Retrieved 9 June 2015. CS1 maint: discouraged parameter (link)
  29. Coward J, Kulbe H, Chakravarty P, Leader D, Vassileva V, Leinster DA, Thompson R, Schioppa T, Nemeth J, Vermeulen J, Singh N, Avril N, Cummings J, Rexhepaj E, Jirström K, Gallagher WM, Brennan DJ, McNeish IA, Balkwill FR (September 15, 2011). "Interleukin-6 as a therapeutic target in human ovarian cancer". Clin Cancer Res. 17 (18): 6083–96. doi:10.1158/1078-0432.CCR-11-0945. PMC 3182554. PMID 21795409.
  30. 30.0 30.1 Milagre CS, Gopinathan G, Everitt G, Thompson RG, Kulbe H, Zhong H, Hollingsworth RE, Grose R, Bowtell DD, Hochhauser D, Balkwill FR (April 1, 2015). "Adaptive upregulation of EGFR limits attenuation of tumor growth by neutralizing IL6 antibodies, with implications for combined therapy in ovarian cancer". Cancer Res. 75 (7): 1255–64. doi:10.1158/0008-5472.CAN-14-1801. PMC 4384986. PMID 25670170.
  31. "Roche links with UK gov for ground-breaking PAH trial". PharmaTimes Media Ltd. 2016-01-06.
  32. Clinical trial number NCT03644667 for "Tocilizumab in Cardiac Transplantation" at
  33. "China approves use of Roche drug in battle against coronavirus complications". March 4, 2020 – via
  34. "China approves use of Roche arthritis drug for coronavirus patients". Reuters. 2020-03-04.
  35. "Coronavirus, farmaco per curare l'artrite reumatoide efficace su due pazienti con polmonite severa da Covid 19" [Coronavirus, drug to treat rheumatoid arthritis effective on two patients with severe pneumonia from Covid 19] (in Italian). Il fatto quotidiano. 2020-03-09.CS1 maint: unrecognized language (link)
  36. "Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019". National Library of Medicine. March 17, 2020.
  37. "3 patients get better on arthritis drug - English". March 13, 2020.
  38. "Coronavirus, via libera dell'Aifa al farmaco anti-artrite efficace su 3 pazienti e a un antivirale: test in 5 centri". (in italiano). Retrieved 2020-03-14.
  39. "WHO and Roche launch trials of potential coronavirus treatments". SwissInfo.Ch.
  40. Hundt, Melanie A.; Deng, Yanhong; Ciarleglio, Maria M.; Nathanson, Michael H.; Lim, Joseph K. (2020). "Abnormal Liver Tests in COVID‐19: A Retrospective Observational Cohort Study of 1827 Patients in a Major U.S. Hospital Network". Hepatology. doi:10.1002/hep.31487. PMID 32725890. S2CID 220855183.
  41. Belli, Brita, Strong link found between abnormal liver tests and poor COVID-19 outcomes, Yale News, August 6, 2020
  42. "Roche provides an update on the phase III COVACTA trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 associated pneumonia". 29 July 2020. Retrieved 2020-08-18.
  43. Stone, John H.; Frigault, Matthew J.; Serling-Boyd, Naomi J.; Fernandes, Ana D.; Harvey, Liam; Foulkes, Andrea S.; Horick, Nora K.; Healy, Brian C.; Shah, Ruta; Bensaci, Ana Maria; Woolley, Ann E. (2020-10-21). "Efficacy of Tocilizumab in Patients Hospitalized with Covid-19". New England Journal of Medicine. 0 (0): null. doi:10.1056/NEJMoa2028836. ISSN 0028-4793.

External links

External sites: